4//SEC Filing
Onyia Jude 4
Accession 0000914475-25-000149
CIK 0000914475other
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 4:10 PM ET
Size
9.3 KB
Accession
0000914475-25-000149
Insider Transaction Report
Form 4
Onyia Jude
Chief Scientific Officer
Transactions
- Exercise/Conversion
Non-Qualified Stock Option
2025-07-02−20,362→ 95,087 totalExercise: $84.74Exp: 2031-11-29→ Common Stock (20,362 underlying) - Exercise/Conversion
Common Stock
2025-07-02$84.74/sh+20,362$1,725,476→ 38,651 total - Sale
Common Stock
2025-07-02$130.13/sh−20,362$2,649,738→ 18,289 total
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Includes an aggregate of 200 shares purchased on February 28, 2025, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- [F4]Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. These options will expire ten years from the date of grant on November 29, 2031.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001894425
Filing Metadata
- Form type
- 4
- Filed
- Jul 6, 8:00 PM ET
- Accepted
- Jul 7, 4:10 PM ET
- Size
- 9.3 KB